CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 614 enrolled
Drug / intervention
Doxorubicin +3 moredrug
Likely dose
Doxorubicin 60 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00789581
NCT00789581Phase 3Completed
CompareCT.gov

Phase III Study of Doxorubicin/Cyclophosphamide (AC) Followed by Ixabepilone vs. AC Followed by Paclitaxel in Patients With Triple-Negative Early-Stage Breast Cancer

SCRI Development Innovations, LLC·interventional·Posted Nov 13, 2008·Updated Jul 2, 2017

In Brief

A Phase 3 clinical trial evaluating Doxorubicin, Cyclophosphamide, and 2 other interventions for Breast Cancer. Completed, enrolled 614 participants across 70 sites in 2 countries.

Detailed Summary

This is a randomized, Phase III, open-label, multicenter study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesPuerto Rico, United States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 13, 2008
Enrollment StartDec 1, 2008
Primary CompletionDec 1, 2015
Study CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 17.6 years ago

Interventions

Doxorubicindrug

Doxorubicin 60 mg/m2

Cyclophosphamidedrug

Cyclophosphamide 600 mg/m2

Ixabepilone (Ixempra)drug

Ixabepilone 40 mg/m2

Paclitaxel (Taxol)drug

Paclitaxel 80 mg/m2